Expert Opinion: Exploring the Effectiveness and Tolerability of Capsaicin 179 mg Cutaneous Patch and Pregabalin in the Treatment of Peripheral Neuropathic Pain

References

• Kessler TL, Brooks KG. Treatments for neuropathic pain. Clinical Pharmacist. 2017;9(12):1–16.
   Google Scholar
• Nagakura Y. The need for fundamental reforms in the pain research field to develop innovative drugs. Expert Opin Drug Discov. 2017;12(1):39–46. doi:10.1080/17460441.2017.1261108
   PubMed Web of Science ®Google Scholar
• Allegri M, Baron R, Hans G, et al. A pharmacological treatment algorithm for localized neuropathic pain. Curr Med Res Opin. 2016;32(2):377–384. doi:10.1185/03007995.2015.1129321
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol. 2015;14(2):162–173. doi:10.1016/S1474-4422(14)70251-0
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237–251. doi:10.1016/j.pain.2007.08.033
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(Suppl 3):S3–S14. doi:10.4065/mcp.2009.0649
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–1123. doi:10.1111/j.1468-1331.2010.02999.x
   PubMed Web of Science ®Google Scholar
• Pfizer Ltd, New York, USA. Lyrica^® (Pregabalin) 100 Mg Hard Capsules [Summary of Product Characteristics]. 2019.
   Google Scholar
• Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661–669. doi:10.2165/11536200-000000000-00000
   PubMed Web of Science ®Google Scholar
• Gustavsson A, Bjorkman J, Ljungcrantz C, et al. Pharmacological treatment patterns in neuropathic pain-- lessons from Swedish administrative registries. Pain Med. 2013;14(7):1072–1080. doi:10.1111/pme.12095
   Web of Science ®Google Scholar
• Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1(1):CD007076. doi:10.1002/14651858.CD005619.pub3
   PubMed Web of Science ®Google Scholar
• Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019;20(Suppl 1):S2–S12. doi:10.1093/pm/pnz075
   PubMed Web of Science ®Google Scholar
• Blair HA. Capsaicin 8% dermal patch: A review in peripheral neuropathic pain. Drugs. 2018;78(14):1489–1500. doi:10.1007/s40265-018-0982-7
   PubMed Web of Science ®Google Scholar
• Grünenthal GmbH, Aachen, Germany. Qutenza^® (Capsaicin 179 Mg Cutaneous Patch) [Summary of Product Characteristics]. 2019.
   Google Scholar
• Pérez C, Rodríguez MJ, Guerrero A, et al. Consenso experto sobre el uso clínico de los tratamientos por vía tópica en el manejo del dolor neuropático periférico. Rev Soc Esp Dolor. 2013;20(6):308–323. doi:10.4321/S1134-80462013000600005
   Google Scholar
• Pickering G, Martin E, Tiberghien F, Delorme C, Mick G. Localized neuropathic pain: an expert consensus on local treatments. Drug Des Devel Ther. 2017;11:2709–2718. doi:10.2147/DDDT.S142630
   PubMed Web of Science ®Google Scholar
• Sommer C, Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. J Pain Symptom Manage. 2017;53(3):614–629. doi:10.1016/j.jpainsymman.2016.09.015
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. CG173: the pharmacological management of neuropathic pain in adults in non-specialist settings. Published November 20, 2013. Updated July 19, 2019. Available from: https://www.nice.org.uk/guidance/cg173. Accessed April 9, 2020.
   Google Scholar
• Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502. doi:10.1093/bja/aer260
   PubMed Web of Science ®Google Scholar
• Bley K. Effects of topical capsaicin on cutaneous innervation: implications for pain management. Open Pain J. 2013;6(1):81–94. doi:10.2174/1876386301306010081
   Google Scholar
• Moran MM, Szallasi A. Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. Br J Pharmacol. 2018;175(12):2185–2203. doi:10.1111/bph.14044
   PubMed Web of Science ®Google Scholar
• Burness CB, McCormack PL. Capsaicin 8% patch: A review in peripheral neuropathic pain. Drugs. 2016;76(1):123–134. doi:10.1007/s40265-015-0520-9
   Web of Science ®Google Scholar
• Premkumar LS, Sikand P. TRPV1: a target for next generation analgesics. Curr Neuropharmacol. 2008;6(2):151–163. doi:10.2174/157015908784533888
   PubMed Web of Science ®Google Scholar
• Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014;12:44–56. doi:10.2174/1570159X1201140117162802
   PubMed Web of Science ®Google Scholar
• Coderre TJ, Kumar N, Laferriere A, Yu JSC, Leavitt A. Evidence that pregabalin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem. 2010;113(2):552–561. doi:10.1111/j.1471-4159.2010.06625.x
   Web of Science ®Google Scholar
• Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014;5(1):38–56. doi:10.1177/2042098613505614
   PubMedGoogle Scholar
• Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108–113. doi:10.1016/j.coph.2005.11.003
   PubMed Web of Science ®Google Scholar
• Haanpää M, Cruccu G, Nurmikko TJ, et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain. 2016;20(2):316–328. doi:10.1002/ejp.731
   PubMed Web of Science ®Google Scholar
• Cruccu G, Nurmikko TJ, Ernault E, Riaz FK, McBride WT, Haanpää M. Superiority of capsaicin 8% patch versus oral pregabalin on dynamic mechanical allodynia in patients with peripheral neuropathic pain. Eur J Pain. 2018;22(4):700–706. doi:10.1002/ejp.1155
   PubMed Web of Science ®Google Scholar
• van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: A systematic literature review and network meta-analysis. Clin Ther. 2017;39(4):787–803.e18. doi:10.1016/j.clinthera.2017.02.010
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Thomas ET, Lee JJ, Goldacre B, Heneghan CJ. Benefits and harms of pregabalin in the management of neuropathic pain: A rapid review and meta-analysis of randomised clinical trials. BMJ Open. 2019;9(1):e023600. doi:10.1136/bmjopen-2018-023600
   PubMed Web of Science ®Google Scholar
• Iacobucci G. UK government to reclassify pregabalin and gabapentin after rise in deaths. BMJ. 2017;358:j4441. doi:10.1136/bmj.j4441
   Web of Science ®Google Scholar
• Abdulahad AK, Snijder RJ, Panni MK, Riaz FK, Karas AJ. A novel standard to evaluate the impact of therapeutic agents on patient safety – the BURDEN OF THERAPY™©. Contemp Clin Trials Commun. 2016;4:186–191. doi:10.1016/j.conctc.2016.09.003
   PubMedGoogle Scholar
• Hansson P, Jensen TS, Kvarstein G, Strömberg M. Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice. Eur J Pain. 2018;22(5):941–950. doi:10.1002/ejp.1180
   PubMed Web of Science ®Google Scholar
• Mankowski C, Poole CD, Ernault E, et al. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol. 2017;17(1):1–11. doi:10.1186/s12883-017-0836-z
   Web of Science ®Google Scholar
• Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7(12):1106–1112. doi:10.1016/S1474-4422(08)70228-X
   PubMed Web of Science ®Google Scholar
• Brown S, Simpson DM, Moyle G, et al. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two Phase III, randomized, controlled trials. AIDS Res Ther. 2013;10(1):5. doi:10.1186/1742-6405-10-5
   PubMed Web of Science ®Google Scholar
• Clifford DB, Simpson DM, Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr. 2012;59(2):126–133. doi:10.1097/QAI.0b013e31823e31f7
   PubMed Web of Science ®Google Scholar
• Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12:99–109. doi:10.1111/j.1526-4637.2010.01004.x
   PubMed Web of Science ®Google Scholar
• Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305–2313. doi:10.1212/01.wnl.0000314647.35825.9c
   PubMed Web of Science ®Google Scholar
• Irving GA, Backonja M, Rauck R, et al. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain. 2012;28(2):101–107. doi:10.1097/AJP.0b013e318227403d
   PubMed Web of Science ®Google Scholar
• Maihöfner CG, Heskamp ML. Treatment of peripheral neuropathic pain by topical capsaicin: impact of pre-existing pain in the QUEPP-study. Eur J Pain. 2014;18(5):671–679. doi:10.1002/j.1532-2149.2013.00415.x
   PubMed Web of Science ®Google Scholar
• Lantéri-Minet M, Perrot S. QAPSA: post-marketing surveillance of capsaicin 8% patch for long-term use in patients with peripheral neuropathic pain in France. Curr Med Res Opin. 2019;35(3):417–426. doi:10.1080/03007995.2018.1558850
   PubMed Web of Science ®Google Scholar
• Mou J, Paillard F, Turnbull B, Trudeau J, Stoker M, Katz NP. Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. Clin J Pain. 2014;30(4):286–294. doi:10.1097/AJP.0b013e31829a4ced
   Web of Science ®Google Scholar
• Maihöfner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin. 2013;29(6):673–683. doi:10.1185/03007995.2013.792246
   PubMed Web of Science ®Google Scholar
• Sánchez N, Sáiz M, Ochoa D, Muñoz M, Rojo E, Pérez C. Efecto de los polimorfismos de TRPV1 en la respuesta a capsaicina en pacientes con dolor neuropático. Rev Soc Esp Dolor. 2019;26(Suppl 1):67–68.
   Google Scholar
• Li Y, Liu G, Li H, Xu Y, Zhang H, Liu Z. Capsaicin-induced activation of ERK1/2 and its involvement in GAP-43 expression and CGRP depletion in organotypically cultured DRG neurons. Cell Mol Neurobiol. 2013;33(3):433–441. doi:10.1007/s10571-013-9909-8
   Web of Science ®Google Scholar
• Sams-Nielsen A, Orskov C, Jansen-Olesen I. Pharmacological evidence for CGRP uptake into perivascular capsaicin sensitive nerve terminals. Br J Pharmacol. 2001;132(5):1145–1153. doi:10.1038/sj.bjp.0703910
   Web of Science ®Google Scholar
• Gustorff B, Poole C, Kloimstein H, Hacker N, Likar R. Treatment of neuropathic pain with the capsaicin 8% patch: quantitative sensory testing (QST) in a prospective observational study identifies potential predictors of response to capsaicin 8% patch treatment. Scand J Pain. 2013;4(3):138–145. doi:10.1016/j.sjpain.2013.04.001
   PubMedGoogle Scholar
• Mainka T, Malewicz NMM, Baron R, Enax-Krumova EK, Treede RD, Maier C. Presence of hyperalgesia predicts analgesic efficacy of topically applied capsaicin 8% in patients with peripheral neuropathic pain. Eur J Pain. 2016;20(1):116–129. doi:10.1002/ejp.703
   PubMed Web of Science ®Google Scholar
• Baron R, Maier C, Attal N, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain. 2017;158(2):261–272. doi:10.1097/j.pain.0000000000000753
   PubMed Web of Science ®Google Scholar
• Serrano A, Torres D, Veciana M, Caro C, Montero J, Mayoral V. Quantitative thermal testing profiles as a predictor of treatment response to topical capsaicin in patients with localized neuropathic pain. Pain Res Treat. 2017;2017:7425907.
   Web of Science ®Google Scholar
• Martini CH, Yassen A, Krebs-Brown A, et al. A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia.. Eur J Pain. 2013;17(10):1491–1501. doi:10.1002/j.1532-2149.2013.00329.x
   Web of Science ®Google Scholar
• Höper J, Helfert S, Heskamp ML, Maihöfner CG, Baron R. High concentration capsaicin for treatment of peripheral neuropathic pain: effect on somatosensory symptoms and identification of treatment responders. Curr Med Res Opin. 2014;30(4):565–574. doi:10.1185/03007995.2013.869491
   PubMed Web of Science ®Google Scholar
• Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7(4):524–532. doi:10.1037/1040-3590.7.4.524
   Web of Science ®Google Scholar
• Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–406. doi:10.1016/j.jclinepi.2010.07.015
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi:10.1136/bmj.39489.470347.AD
   PubMed Web of Science ®Google Scholar
• Deng Y, Luo L, Hu Y, Fang K, Liu J. Clinical practice guidelines for the management of neuropathic pain: a systematic review. BMC Anesthesiol. 2016;16(1):12. doi:10.1186/s12871-015-0150-5
   Web of Science ®Google Scholar
• Legido-Quigley H, Panteli D, Brusamento S, et al. Clinical guidelines in the European Union: mapping the regulatory basis, development, quality control, implementation and evaluation across member states. Health Policy. 2012;107(2–3):146–156. doi:10.1016/j.healthpol.2012.08.004
   Web of Science ®Google Scholar